Business Breakfast
Congress Centre, Business Breakfast Hall 2

In recent years, Russia has charted a clear course for domestic pharmaceutical production, targeting an almost doubling of in-country production with the aim of reaching 50% by 2020. At the same time, there are plans to bring the legal framework for the drug market in line with international standards. How is this policy being implemented, and how might it impact both foreign and domestic producers over the coming years? What main problems are being encountered by the sector and what should be done to overcome these issues? What steps need to be taken to ensure that Russian patients have uninterrupted access to quality medicines?

Dmitry Pushkar , Chief Urologist, Ministry of Healthcare of the Russian Federation
Ramil Khabriev , Director, N.A. Semashko National Research Institute of Public Health

Daniel Brindle , Vice-President, Government Affairs, Emerging Markets Asia Pacific, GSK (GlaxoSmithKline)
Elena Bushberg , General Director, Veropharm
Victor Dmitriev , General Manager, Association of Russian Pharmaceutical Manufacturers
Elena Kartasheva , General Director, Abbott Russia
Eric Cornut , Chief Ethics, Compliance and Policy Officer, Novartis AG
Hugues Lebeau , Vice-President for Public Affairs, Sanofi
Dmitry Morozov , President, BIOCAD
Mikhail Murashko , Head, Federal Service on Surveillance in Healthcare
Vladimir Potemkin , Deputy Governor of Kaluga Region
Iskra Reic , Vice-President, Russia and Eurasia Area, AstraZeneca; General Manager, AstraZeneca Russia
Alexey Repik , President, Delovaya Rossiya (Business Russia)
Sergey Tsyb , Deputy Minister of Industry and Trade of the Russian Federation
Vladimir Shipkov , Executive Director, Association of International Pharmaceutical Manufacturers (AIPM)


Key moments

It is necessary to develop our national competences for creating our own innovative medicines.
Sergey Tsyb
There must be an equal playing field for absolutely all companies, equal terms for the medicines to access the market and equal terms of regulatory procedures.
Sergey Tsyb
The question is not where to manufacture but where to develop, where the center of competence is located. Today’s Russia has ample potential for such developments.
Alexander Elinson